Abstract
Background: Nimotuzumab is a humanized anti-epidermal increase element receptor (EGFR) antibody that has proven preclinical and clinical anticancer activity in cerebral glioblastoma multiforme (GBM). We conducted a section II, single-arm, multicenter scientific trial to assess the advantage of including nimotuzumab to modern-day trendy chemo-radiotherapy for patients with GBM with advantageous EGFR expression.
Methods: Newly identified sufferers with histologically proven unmarried supratentorial GBM and epidermal boom component receptor (EGFR) fantastic expressions were recruited. All sufferers were dealt with with nimotuzumab, administered as soon as a week intravenously for six weeks further to radiotherapy with concomitant and adjuvant temozolomide after surgery. The primary endpoints have been usual survival (OS) and development-loose survival (PFS). Secondary objectives protected objective response fee (ORR) and toxicity.
Results: A overall of 39 sufferers had been enrolled and 36 patients were evaluated for efficacy. The ORR at the end of RT become seventy two.2%. Median OS and PFS have been 24.five and 11.nine months. The 1-year OS and PFS rates have been 83.3% and 49.three%. The 2-yr OS and PFS rates were 51.1% and 29.zero%. O (6)-methylquanine DNA methyl-tranferase (MGMT) expression is known to affect the efficacy of chemotherapy and status of its expression is examined. No full-size correlation between remedy effects and MGMT repute was found. Most frequent treatment-related toxicities have been moderate to slight and protected constipation, anorexia, fatigue, nausea, vomiting, and leucopenia.
Conclusions: Our observe display that nimotuzumab similarly to wellknown treatment is nicely tolerable and has extended survival in newly recognized GBM sufferers with EGFR high-quality expression.
Keywords: glioblastoma, radiotherapy, temozolomide, nimotuzumab, epidermal boom issue receptor, O (6)-methylquanine DNA methyl-tranferase (MGMT)
Background
Glioblastoma multiforme (GBM) is the maximum common and aggressive number one brain tumor in adults, accounting for approximately 60-70% of gliomas [1]. Due to the resistance of GBM cells to remedy and its invasive nature, GBM sufferers have poor outcomes, with much less than 5% of patients surviving up to five years after diagnosis [2]. The modern standard remedy for newly recognized GBM includes maximal safe resection observed by radiotherapy (RT) and concomitant temozolomide (TMZ) chemotherapy and up to six months of adjuvant TMZ (TMZ/RT→TMZ). However, this strategy most effective successfully extended the median survival time to 14.6 months [3]. Most GBM sufferers nonetheless dies within 2 years, necessitating exploration of other treatment options.
The epidermal growth component receptor (EGFR), a tyrosine kinase receptor, become discovered as a proto-oncogene [4]. The overexpression of EGFR and its ligands in several carcinomas and their association with competitive tumor improvement provides a reason for selectively concentrated on this signal pathway. EGFR is also one in all the maximum promising treatment goals for patients with GBM after the demonstration of gene amplification and protein overexpression in some GBM tumors [5-7]. It has been stated that approximately half of those tumors overexpression is the result of a mutant form of the receptor known as as EGFR variation III mutant (EGFRvIII). EGFRvIII has a kinase area that ends in constitutive signaling pathway activation, further decorate tumorigenic interest, promote tumor progression and drug resistance [8,9].
Nimotuzumab is a humanized anti-EGFR antibody, which has been extensively evaluated and granted popularity of use in sufferers with head and neck squamous carcinoma [10,11]. Recently, numerous clinical trials have confirmed the scientific activity of nimotuzumab in treating adult high-grade glioma patients [12-17]. However, the impact of adding nimotuzumab to modern-day general TMZ/RT→TMZ remains controversial. Thus, this look at aimed to analyze the medical benefit and safety of including nimotuzumab to the popular remedy for patients with newly recognized GBM. Since O (6)-methylquanine DNA methyl-tranferase (MGMT) expression impacts efficacy of TMZ treatment, we also look at the effect of including nimotuzumab to modern-day fashionable TMZ/RT→TMZ in MGMT expression patients.
Patients and Methods
Study Design
This multicenter, unmarried-arm, section II trial investigated the efficacy and safety of nimotuzumab added to TMZ/RT→TMZ in sufferers with newly recognized GBM (ClinicalTrials.Gov identifier NCT03388372). The take a look at became approved via the Institutional Review Board of Sun Yat-sen University Cancer Center, and was performed in accordance with the Good Clinical Practice guideline. The ethics approval became for all of the look at sites. The investigator received signed informed consent shape from sufferers for approval of treatment and for private statistics use in research without violating their privacy. The number one endpoints were the general survival (OS) and development-loose survival (PFS). Secondary endpoints had been objective response fee (ORR) and protection. The influence of MGMT expression popularity on efficacy turned into investigated in a prospectively deliberate subgroup analysis.
Patients
Main inclusion criteria had been age between 18 – 75 years; newly identified, histologically proven single supratentorial GBM (WHO grade 4); EGFR tremendous; >50% of the gross tumor quantity eliminated by way of surgical procedure; Karnofsky overall performance score (KPS) ≥ 60; and good enough renal function (creatinine ≤1.five × upper limit of normal [ULN] or creatinine clearance ≥ 60 mL/min), hepatic function (total bilirubin ≤1.five × ULN and serum transaminases ≤three × ULN), and hematologic function (white blood mobile count ≥ three,000/uL or absolute neutrophil count ≥ 1,500/uL, platelets ≥ a hundred,000/uL, and hemoglobin ≥ 10 g/dL). Tumor tissue turned into required for primary pathology evaluation and re-checking EGFR and MGMT expression status. An c program languageperiod of 2 to 6 weeks among surgical treatment and RT turned into required.
The exclusion criteria had been terrible EGFR expression, earlier chemotherapy, anti-EGFR therapy, RT, or a records of malignancy in the previous 5 years. Patients with severe complications or lively infection, continuous vomiting that could intrude with the oral management of TMZ were also excluded. A negative pregnancy take a look at and adequate contraception were mandatory.
Treatment
All patients had obtained surgical operation beneath the principle of most secure resection of tumors with as a minimum 50% of the gross tumor quantity removed. Fractionated three-dimensional conformal RT become given at 2.zero Gy in line with fraction with five each day fractions in keeping with week for 6 weeks. Gross tumor extent (GTV) delineation changed into based at the resection hollow space plus any residual enhancing tumor on contrast-improved T1 weighted magnetic resonance imaging (MRI) and region of hyperintensity on FLAIR/T2 whilst suspicious for tumor as opposed to edema. The clinical target extent-1 (CTV1) was defined as GTV with a 2 cm margin and CTV2 became defined as GTV with a 1 cm margin. CTVs with zero.3 cm margins have been defined as making plans tumor volumes (PTVs). The prescription doses were 50 Gy to PTV1 and 60 Gy to PTV2. TMZ at 75 mg/m2 daily changed into administered orally from the first to the closing day of RT. After a four-week break, individualized adjuvant TMZ regimen changed into given based totally on MGMT expression reputation. The preferred five-day schedule every 4 weeks for 6 cycles was given for sufferers with bad MGMT expression. The dose become 150mg/m2 for the primary cycle and 200 mg/m2 starting from the second one cycle. The 7-day on/7-day off schedule every 2 weeks for twelve cycles changed into given for patients with tremendous MGMT expression. The dose was 100 mg/m2 for the primary two cycles and one hundred fifty mg/m2 beginning from the 0.33 cycle.
Nimotuzumab of 200 mg turned into administered as an over 1-hour intravenous infusion as soon as weekly, starting from the primary week and continuing until the remaining week of RT for a complete of 6 times.
EGFR and MGMT Status
EGFR and MGMT expression were decided with the aid of immunohistochemistry analysis, the use of commercially to be had detection kits (Ascend Biotechnology, China) and automatic staining techniques (Benchmark XT, Ventana, and Autostainer Link 48, Dako). EGFR fine expression changed into defined as >10% of cells stained positive. Two pathologists independently interpreted the results with none clinical or other histological statistics.
Efficacy and Safety Assessments
MRI scan turned into achieved both earlier than surgery and inside 24 – 72 hours after surgical operation to perceive residue ratio. MRI turned into additionally finished inside 2 weeks earlier than RT to formulate RT plan, repeated at the stop of RT and each three months thereafter to evaluate clinical efficacy. Treatment responses had been evaluated in line with RANO’s criteria [18]. The tumor progression changed into described via the incidence of any of the following: the sum of the products of perpendicular diameters of target enhancing lesions is extended by using ≥ 20% for patients receiving solid or growing doses of corticosteroids; a big boom in T2/FLAIR nonenhancing lesions for patients receiving strong or growing doses of corticosteroids; the advent of any new lesions; clear progression of unmeasurable lesions; or precise clinical deterioration now not due to different causes aside from the tumor. When there has been tumor development, sufferers had been handled at the investigator’s discretion, and the regimen of second-line remedy became recorded.
Safety became evaluated by means of unfavourable events (AEs), laboratory assessments, and bodily examinations, together with KPS, neurologic examinations, weekly blood counts, serum chemistry, urinalysis, chest x-ray, and ECG. All AEs were recorded in line with Common Toxicity Criteria model three.0, and the AEs probable related to remedy with TMZ/RT or nimotuzumab or now not otherwise attributed to different causes had been stated as treatment-associated AEs. AEs have been suggested one by one for the RT period and the adjuvant-remedy duration. The former turned into defined as from day 1 of RT to28 days after the closing day of RT, or to the first day of adjuvant TMZ therapy. The latter was described as from the first day of adjuvant TMZ therapy to the thirty fifth days considering the fact that day 1 of the closing cycle of TMZ.
Statistical analysis
This examine used Simon’s most reliable -degree design, which was formulated to differentiate a positive one-yr OS fee of 87% from a control price of 66% with 90% power [3,19], at a importance level of zero.05. In total, 35 patients need to be enrolled.
The analyses have been completed at the in line with-protocol population, described as patients who received at the least four cycles of nimotuzumab and as a minimum four weeks of concomitant TMZ. PFS became described as time from surgical operation to progression or death from any cause. OS turned into defined as time from surgery to dying from any cause. All calculations have been carried out the usage of Statistical Package for the Social Sciences, version 20.zero (SPSS, Chicago, IL, USA). Survival curves were made with the Kaplan-Meier technique and as compared with the log-rank take a look at. Cox proportional hazards version became applied to adjust for stratification elements and different confounding variables. Two-tailed P-values < 0.05 had been considered great.
Results
Patient traits
From August 2010 to July 2015, 39 sufferers from 6 institutions were recruited, three patients with showed protocol deviation have been removed from the analysis (one started RT after a postpone of 19.3 weeks after surgery; one received different anti-tumor remedy after RT; one has not completed RT because of personal reason). Among the 36 consistent with-protocol patients, 20 (55.6%) had positive MGMT expression. EGFR immunohistochemistry showed strong nice staining on mobile membrane of all the patients (Figure 1), which changed into in regular with the end result mentioned via Yoon et al [20]. The patient characteristics are shown in Table 1.
Treatment Delivery
All 36 patients completed the remedy with nimotuzumab plus concomitant TMZ/RT. Among them, 32 (88.9%) sufferers completed at the least one cycle of adjuvant TMZ and 4 (11.1%) did not enter the adjuvant-therapy length due to tumor progression. Twenty-4 (66.7%) patients completed all 6 deliberate cycles of adjuvant TMZ. One (2.8%) patient completed five cycles, 2 (5.6%) sufferers completed 3 cycles, one (2.8%) patient finished 2 cycles and four (11.1%) sufferers completed one cycle. Reasons for early discontinuation of adjuvant TMZ (1 – five cycles) were tumor development (four patients; 11.1%), AEs (2 patients; five.6%), or other non-public reasons (2 patient; 5.6%).
The post Efficacy and safety of nimotuzumab in addition to radiotherapy a phase II multicenter clinical trial appeared first on drugscaps.
source https://www.drugscaps.com/efficacy-and-safety-of-nimotuzumab-in-addition-to-radiotherapy-a-phase-ii-multicenter-clinical-trial/